Where AI meets biology — the breakthroughs changing diagnosis, treatment, and prevention. Daily coverage of AI drug discovery, digital therapeutics, FDA milestones, and the startups building the future of healthcare.
Blog / RSS8 sources · 50 posts
<a href="https://www.fiercebiotech.com/biotech/novartis-ceo-continuing-evaluate-vivo-car-ts-no-deals-works" hreflang="en">Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works</a>
fiercebiotech.com·Apr 28, 2026
Novartis is currently evaluating the in vivo CAR-T space, but CEO Vas Narasimhan stated there are no immediate acquisition plans despite the company's interest in this area. The company is focusing on its immune reset portfolio, particularly the rapcabtagene autoleucel therapy for blood cancers and autoimmune conditions, while also engaging in strategic acquisitions to bolster its pipeline against generic competition.
For a professional tracking healthtech and biotech investments, the key insight is that while Novartis is actively evaluating the in vivo CAR-T space, they currently have no plans for acquisitions. Ho...
<a href="https://www.fiercebiotech.com/biotech/boehringer-links-dual-agonist-166-weight-loss-phase-3-leaves-key-questions-unanswered" hreflang="en">Boehringer links dual agonist to 16.6% weight loss in phase 3, but leaves key questions unanswered</a>
fiercebiotech.com·Apr 28, 2026
Boehringer Ingelheim's dual agonist, survodutide, achieved a 16.6% weight loss in a phase 3 trial, which is competitive but below the efficacy of existing obesity treatments. While the drug shows potential for improving liver health and reducing visceral fat, key questions about its tolerability and overall benefits remain unanswered.
Boehringer Ingelheim's phase 3 trial results for survodutide, a glucagon/GLP-1 dual agonist, suggest potential advantages in targeting cardiometabolic risk and improving liver health, although signifi...
Get this feed in your inbox
Free digest emails with the latest posts — no account needed.
Revolution Medicines threatens to sue Erasca over patent, efficacy claims
endpts.com·Apr 27, 2026
Revolution Medicines is threatening to sue Erasca over patent and efficacy claims related to a new cancer drug, escalating a legal dispute in the biotech industry. This conflict highlights the competitive landscape surrounding RAS-targeted therapies.
This content highlights an ongoing legal battle between Revolution Medicines and Erasca over patent and efficacy claims related to RAS cancer drugs. For a professional in healthtech and biotech, this ...
Diaceutics, Experian partner to push diagnostic data into pharma ad targeting
mobihealthnews.com·Apr 27, 2026
Diaceutics and Experian have partnered to integrate real-time diagnostic data into pharmaceutical marketing workflows, enabling targeted engagement with clinicians during critical treatment decision moments. This collaboration aims to enhance the precision of healthcare marketing by shifting focus from historical data to real-time clinical insights, allowing for more effective and timely campaigns.
The partnership between Diaceutics and Experian offers a significant advancement for pharmaceutical marketers by integrating real-time diagnostic data into marketing workflows. This allows for precise...
STAT+: Astellas retries XLMTM gene therapy after deaths
statnews.com·Apr 27, 2026
Astellas is reintroducing its XLMTM gene therapy into clinical trials after previous incidents of patient deaths, while other biotech news highlights Veradermics' successful late-stage trial for a hair loss pill and promising results from Intellia's CRISPR therapy for hereditary angioedema.
Intellia Therapeutics' CRISPR-based treatment for hereditary angioedema has achieved significant results in a Phase 3 trial, reducing attack rates by 87% and positioning itself as a potential function...
<a href="https://www.fiercebiotech.com/biotech/seaport-hemab-chart-courses-180m-ipos-fund-depression-clotting-candidates" hreflang="en">Seaport, Hemab chart courses for $180M IPOs to fund depression, clotting candidates</a>
fiercebiotech.com·Apr 27, 2026
Seaport Therapeutics and Hemab Therapeutics are both planning to raise approximately $180 million each through IPOs to fund their respective drug candidates for depression and clotting disorders. Seaport aims to advance its depression treatment SPT-300, while Hemab focuses on developing its bispecific antibody sutacimig for bleeding disorders.
The resurgence of biotech IPOs is highlighted by Seaport and Hemab Therapeutics, both aiming to raise around $180 million to advance their respective drug candidates. Seaport is focusing on depression...
Veradermics wins at growing hair with oral Rogaine in first key test as a public company
endpts.com·Apr 27, 2026
Veradermics has successfully completed its first major trial as a public company, demonstrating that its oral version of Rogaine effectively promotes hair growth in a late-stage trial.
There is no relevant insight from this content for a professional interested in healthtech, biotech, digital health, telemedicine, or AI drug discovery, as it primarily discusses Veradermics' success ...
AI biotech Fathom raises $47M Series A, renames from Atommap
endpts.com·Apr 27, 2026
Fathom Therapeutics, formerly known as Atommap, has raised $47 million in a Series A funding round to enhance its drug discovery efforts by integrating artificial intelligence and physics. The company aims to leverage advanced computational techniques in its research initiatives.
Fathom Therapeutics' successful $47M Series A funding round emphasizes the growing investor confidence in companies that integrate AI with traditional scientific approaches, such as physics, to enhanc...
STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
statnews.com·Apr 27, 2026
Oruka Therapeutics has reported promising results for its long-acting injectable treatment for plaque psoriasis, ORKA-001, which achieved complete skin clearance in 63% of patients during a mid-stage trial. If these results are confirmed in late-stage trials, the drug could offer a new treatment option with fewer injections compared to existing therapies.
Oruka Therapeutics' ORKA-001, a long-acting injectable treatment for plaque psoriasis, has shown promising results in a mid-stage trial with 63% of patients achieving complete skin clearance. If these...
<a href="https://www.fiercebiotech.com/biotech/compass-therapeutics-stock-heads-south-after-cancer-bispecific-misses-overall-survival" hreflang="en">Compass Therapeutics’ stock heads south after cancer bispecific misses on overall survival</a>
fiercebiotech.com·Apr 27, 2026
Compass Therapeutics' stock plummeted by 53% after its bispecific antibody, tovecimig, failed to meet the overall survival endpoint in a phase 2/3 study for advanced biliary tract cancer, despite showing some improvements in progression-free survival. The company plans to discuss the data with the FDA as it prepares for a potential approval filing, but analysts express concerns about the implications of the survival miss on the drug's approvability.
Compass Therapeutics' recent phase 2/3 trial results for their bispecific antibody, tovecimig, highlight the critical importance of robust clinical trial design, especially in managing crossover effec...
<a href="https://www.fiercebiotech.com/biotech/astellas-thins-early-pipeline-swaps-out-struggling-rare-disease-gene-therapy" hreflang="en">Astellas thins early pipeline, swaps out struggling rare disease gene therapy</a>
fiercebiotech.com·Apr 27, 2026
Astellas Pharma has streamlined its early pipeline by halting development of its gene therapy AT132 for X-linked myotubular myopathy, incurring a loss of approximately $103 million, and instead is focusing on a new gene therapy candidate, ASP2957, which shows promise in preclinical studies. Additionally, the company has discontinued two phase 1 candidates, ASP5502 and ASP1570, as part of a strategic decision to concentrate resources on more promising assets.
Astellas Pharma's strategic shift from the troubled gene therapy AT132 to ASP2957, which shows high muscle specificity and reduced liver targeting, highlights a focus on refining delivery mechanisms i...
<a href="https://www.fiercebiotech.com/pharma/ligand-snaps-fellow-biotech-royalty-aggregator-xoma-739m" hreflang="en">Ligand snaps up fellow biotech royalty aggregator Xoma for $739M</a>
fiercebiotech.com·Apr 27, 2026
Ligand Pharmaceuticals has announced its acquisition of fellow biotech royalty aggregator Xoma for approximately $739 million, which is expected to enhance Ligand's portfolio significantly by adding over 120 assets, including late-stage developments. The deal, set to close in the third quarter of 2026, aims to capitalize on synergies and bolster Ligand's financial outlook, with revised revenue projections following the acquisition.
The acquisition of Xoma by Ligand Pharmaceuticals for $739 million highlights the strategic value of biotech royalty aggregation as a business model, particularly for companies focusing on late-stage ...
<a href="https://www.fiercebiotech.com/biotech/orukas-psoriasis-data-hailed-outright-win-over-skyrizi-spurring-big-blockbuster-forecasts" hreflang="en">Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts</a>
fiercebiotech.com·Apr 27, 2026
Oruka Therapeutics' psoriasis treatment, ORKA-001, demonstrated significant efficacy in a phase 2a trial, achieving complete skin clearance in 63.5% of patients, which analysts predict could lead to sales of up to $10 billion, surpassing AbbVie's Skyrizi. The promising results, including a potential for annual dosing, have prompted Oruka to prepare for a phase 3 trial.
Oruka Therapeutics' ORKA-001 has shown unprecedented efficacy in a phase 2a trial for plaque psoriasis, surpassing AbbVie's Skyrizi in skin clearance rates with a potential for annual dosing. This pos...
<a href="https://www.fiercebiotech.com/biotech/intellia-races-vivo-crispr-therapy-fda-after-phase-3-data-paint-compelling-picture" hreflang="en">Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture</a>
fiercebiotech.com·Apr 27, 2026
Intellia Therapeutics has announced positive phase 3 trial results for its CRISPR-based gene-editing therapy, lonvoguran ziclumeran (lonvo-z), which significantly reduced swelling attacks in patients with hereditary angioedema, leading the company to initiate a rolling submission for FDA approval. The therapy demonstrated a compelling efficacy profile, with a one-time infusion resulting in an 87% reduction in attacks compared to placebo, positioning it as a potentially transformative treatment option in the market.
Intellia Therapeutics' phase 3 trial results for their in vivo CRISPR therapy, lonvoguran ziclumeran (lonvo-z), demonstrated a significant reduction in hereditary angioedema attacks, positioning it as...
<a href="https://www.fiercebiotech.com/medtech/thermo-fisher-scientific-sells-microbiology-biz-1b-european-equity-firm" hreflang="en">Thermo Fisher Scientific sells microbiology business for $1B to European private equity firm</a>
fiercebiotech.com·Apr 27, 2026
Thermo Fisher Scientific has sold its microbiology business to the European private equity firm Astorg for $1.075 billion, following initial rumors of the sale last year. The unit, which focuses on antimicrobial susceptibility testing and culture media solutions, generated $645 million in revenue in 2025 and will now operate independently under Astorg's management.
For a professional interested in healthtech and biotech, the key insight is that Thermo Fisher Scientific's sale of its microbiology business to Astorg for $1.075 billion presents potential opportunit...
Tandem Diabetes Care has issued an urgent software correction for its Mobi insulin pumps to address a malfunction that can prevent insulin delivery, potentially leading to severe hyperglycemia. The FDA has classified the recall as Class I, affecting over 17,700 devices, with reports of serious injuries but no fatalities.
The most valuable insight for a professional tracking healthtech and medtech developments is the urgent need for software reliability in medical devices like insulin pumps. Tandem Diabetes Care's Clas...
<a href="https://www.fiercebiotech.com/biotech/lilly-continues-ma-streak-23b-deal-next-gen-jak-inhibitor-biotech-ajax" hreflang="en">Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax</a>
fiercebiotech.com·Apr 27, 2026
Eli Lilly has continued its acquisition spree by purchasing Ajax Therapeutics for $2.3 billion to advance its clinical-stage JAK2 inhibitor, AJ1-11095, aimed at treating myelofibrosis. The drug is expected to offer deeper efficacy and a new treatment option for patients resistant to existing therapies.
Eli Lilly's acquisition of Ajax Therapeutics, centered around an innovative Type II JAK2 inhibitor for myelofibrosis, underscores the potential market shift towards more effective treatments for patie...
<a href="https://www.fiercebiotech.com/biotech/british-biotech-vc-funding-shows-signs-recovery-ipo-rebound-yet-materialize" hreflang="en">British biotech VC funding shows ‘signs of recovery,’ but IPO rebound yet to materialize</a>
fiercebiotech.com·Apr 27, 2026
British biotech funding has seen a promising recovery, with £552 million raised in Q1 2026, up from £466 million in Q4 2025, indicating a more active investment environment; however, the anticipated rebound in IPOs has not yet occurred, as no new public listings were recorded during the quarter.
The key insight for you is that while British biotech VC funding is showing signs of recovery with increased investment across various stages, the IPO market remains stagnant without any new public li...
<a href="https://www.fiercebiotech.com/medtech/blood-test-powered-ai-shows-early-promise-monitoring-rare-childhood-cancer" hreflang="en">Blood test powered by AI shows early promise in monitoring rare childhood cancer</a>
fiercebiotech.com·Apr 27, 2026
Researchers have developed a promising AI-powered liquid biopsy test for Ewing sarcoma, a rare childhood cancer, which may allow for earlier detection and monitoring by identifying cancer DNA in blood samples. Initial results show the test successfully detected signs of cancer in patients whose disease had returned, indicating its potential as a less invasive diagnostic tool.
The most valuable insight for a professional in healthtech and biotech is the potential of AI-driven liquid biopsies to transform cancer diagnostics, particularly for hard-to-detect childhood cancers ...
<a href="https://www.fiercebiotech.com/medtech/endoscopic-procedure-can-help-slow-weight-rebound-glp-1-treatment-study" hreflang="en">Endoscopic procedure can help slow weight rebound from stopping GLP-1 treatment: study</a>
fiercebiotech.com·Apr 26, 2026
A recent study suggests that the endoscopic procedure known as duodenal mucosal resurfacing may help patients maintain weight loss after discontinuing GLP-1 obesity treatments like Eli Lilly's tirzepatide, reducing weight rebound significantly compared to those who did not undergo the procedure. The findings indicate that patients who received the treatment regained less weight and maintained over 80% of their weight loss six months post-cessation of the medication.
Fractyl Health's duodenal mucosal resurfacing, currently used in Europe for type 2 diabetes, shows promise in preventing weight rebound post-GLP-1 treatment, as demonstrated in the REMAIN-1 trial with...
Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
endpts.com·Apr 25, 2026
The Endpoints Weekly highlights significant developments in the biopharma sector, including Sanofi's reevaluation of its immunology strategy, Lilly's acquisition of an in vivo CAR-T biotech, and RevMed's notable advancements in cancer treatment.
The content provided does not offer a specific insight relevant to the reader's interests in healthtech, biotech, digital health, telemedicine, AI drug discovery, or related fields. If you are trackin...
Thermo Fisher Scientific reported a strong first quarter in 2026, with revenues rising 6% to $11.01 billion, driven by high demand from biopharma customers and the recent acquisition of Clario, which contributed additional revenue. The company also increased its revenue and earnings guidance for the year, citing growth opportunities in artificial intelligence and ongoing market resilience despite inflationary pressures.
Thermo Fisher's strategic acquisition of Clario and its collaboration with Nvidia to enhance AI-driven laboratory infrastructure highlight significant investment opportunities in AI integration and da...
STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
statnews.com·Apr 24, 2026
Eli Lilly is acquiring Kelonia Therapeutics, a struggling cancer startup that nearly ran out of cash multiple times, for $3.2 billion, with potential milestone payments that could double the amount. Bryan Roberts from Venrock discussed the reasons behind this significant deal, highlighting Kelonia's innovative cell therapies for cancer and autoimmune diseases.
The key insight for a professional interested in biotech and pharmaceutical investments is Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion, despite the latter's previous financial str...
STAT+: Up and down the ladder: The latest comings and goings
statnews.com·Apr 24, 2026
The article discusses recent personnel changes in the pharmaceutical industry, highlighting new hires, promotions, and departures, including Tenpoint Therapeutics hiring Stephen Lane as their chief medical officer. It encourages industry insiders to share updates about staffing changes.
The content primarily discusses personnel changes within the pharmaceutical industry, highlighting the hiring of Stephen Lane as Chief Medical Officer at Tenpoint Therapeutics. For someone tracking he...
<a href="https://www.fiercebiotech.com/biotech/compass-usona-score-fda-national-priority-vouchers-amid-trump-administrations-psychedelic" hreflang="en">Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push</a>
fiercebiotech.com·Apr 24, 2026
The FDA has awarded national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics to expedite the development of psychedelic treatments for mental health disorders, in line with the Trump administration's push to enhance access to such therapies. These vouchers will facilitate improved communication with the FDA and accelerate the review process for their respective psilocybin and methylone treatments.
The FDA's issuance of national priority vouchers to companies like Compass Pathways and Transcend Therapeutics underscores a significant regulatory shift towards accelerating the development and appro...
Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug
endpts.com·Apr 24, 2026
Avalyn Pharma is planning a $182 million IPO to support its development of inhaled versions of existing pulmonary fibrosis treatments, while Novartis' malaria drug has received prequalification from the WHO.
Avalyn Pharma's planned $182 million IPO to develop inhaled versions of approved pulmonary fibrosis medicines indicates a significant investment opportunity in respiratory health innovations. This mov...
<a href="https://www.fiercebiotech.com/cro/wcg-acquires-contract-network-aiming-streamline-clinical-trial-process" hreflang="en">WCG acquires The Contract Network in bid to streamline clinical trial execution</a>
fiercebiotech.com·Apr 24, 2026
WCG is acquiring The Contract Network to enhance its clinical trial execution by integrating AI technology that streamlines contract and study start-up workflows. This acquisition aims to simplify complex tasks in clinical research, improving decision-making and efficiency within WCG's ClinSphere platform.
The acquisition of The Contract Network by WCG highlights a strategic move towards integrating AI to streamline clinical trial processes, particularly in contract management and site enablement. This ...
<a href="https://www.fiercebiotech.com/biotech/avalyn-aims-181m-ipo-fund-phase-3-trials-reformulated-respiratory-drugs" hreflang="en">Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs </a>
fiercebiotech.com·Apr 24, 2026
Avalyn Pharma is seeking to raise approximately $182 million through an IPO to fund phase 3 trials of its inhaled formulations of existing respiratory drugs, specifically targeting idiopathic pulmonary fibrosis. The company plans to use the proceeds to advance its lead drug, AP01, and other assets through clinical development stages.
Avalyn Pharma's planned $182 million IPO to advance its inhaled respiratory drugs into phase 3 trials signals a strong investment opportunity in the biotech sector, particularly in the development of ...
<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-helus-shuffles-out-ceo-after-two-months-adds-experienceto-science-board" hreflang="en">Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board</a>
fiercebiotech.com·Apr 24, 2026
Helus Pharma has replaced CEO Michael Cola after just two months, with co-founder Eric So stepping in as interim CEO while the company strengthens its scientific advisory board. Additionally, Pfizer's chief strategy officer Andrew Baum is leaving, and Paratus Sciences has appointed Alicia Secor as its new CEO to advance its lead drug candidate.
Helus Pharma's recent CEO shuffle highlights the importance of adaptable leadership in advancing next-gen mental health therapies. With industry veterans like Robert Langer and Stephen Brannan joining...
<a href="https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo" hreflang="en">After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?</a>
fiercebiotech.com·Apr 24, 2026
Eli Lilly's $7 billion acquisition of Kelonia Therapeutics highlights the intense competition among pharmaceutical companies for in vivo CAR-T technologies, following several high-profile deals in the sector. However, experts predict a slowdown in future acquisitions due to a dwindling number of viable targets, with Umoja Biopharma being one of the few remaining options for potential buyers.
Eli Lilly's $7 billion acquisition of Kelonia Therapeutics highlights the high valuations and strong interest in the in vivo CAR-T space, driven by its potential to disrupt traditional CAR-T therapy. ...
Regeneron Gets Landmark FDA Approval for First Gene Therapy for Hearing Loss - MedCity News
medcitynews.com·Apr 23, 2026
The FDA has approved Regeneron's gene therapy, Otarmeni, as the first treatment for inherited hearing loss caused by OTOF gene mutations, potentially restoring normal acoustic hearing. Unlike traditional mechanical implants, this one-time therapy uses an engineered virus to deliver a functioning OTOF gene to inner ear cells, with promising early results showing significant hearing improvement in treated patients.
Regeneron's FDA approval for Otarmeni, a gene therapy for OTOF-related hearing loss, highlights a significant advancement in precision medicine and gene therapy within the biotech sector. This approva...
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
statnews.com·Apr 23, 2026
The latest episode of "The Readout LOUD" discusses the acquisition of Kelonia Therapeutics, a CAR-T biotech that was on the brink of closure, by Eli Lilly for $3.25 billion, and examines the strategies drugmakers are employing to increase prescription rates through partnerships with telehealth providers.
The most valuable insight for someone tracking healthtech and biotech is the acquisition of Kelonia Therapeutics, a CAR-T biotech, by Eli Lilly for $3.25 billion. This highlights a significant turnaro...
FDA approves Regeneron's hearing loss gene therapy Otarmeni
endpts.com·Apr 23, 2026
Regeneron has received FDA approval for the first gene therapy aimed at treating a rare inherited form of hearing loss, and has also finalized a pricing agreement in the U.S.
Regeneron has achieved a significant milestone by securing the first FDA approval for a gene therapy targeting a rare form of inherited hearing loss. This development highlights the growing potential ...
Substance use disorder biotech Tempero to close after earlier 'serious' safety event
endpts.com·Apr 23, 2026
Tempero Bio, a biotech company focused on treating substance use disorders, is shutting down operations following a serious safety event. The company's ambitious plans to innovate in this area have ultimately led to its closure.
The most valuable insight for you is that Tempero Bio, a biotech company focused on substance use disorders, is closing due to a serious safety event. This highlights the critical importance of safety...
STAT+: Sanofi research priorities in flux as new CEO logs in
statnews.com·Apr 23, 2026
Sanofi's research priorities are shifting under new CEO Belén Garijo, who may reconsider the company's focus on immunology due to recent disappointing results. Additionally, a gene therapy for deafness is showing promising real-world benefits, while concerns arise over the implications of ultra-cheap telehealth options on patient care.
The article mentions that Sanofi's research priorities are in flux with the arrival of new CEO Belén Garijo, raising questions about whether the company will continue its focus on immunology despite r...
<a href="https://www.fiercebiotech.com/biotech/pfizer-ends-work-phase-1-stage-immunostimulatory-drug-conjugate-cancer-patients" hreflang="en">Pfizer cans work on next-gen conjugate in cancer patients</a>
fiercebiotech.com·Apr 23, 2026
Pfizer has terminated its phase 1 study of the PD-L1-targeting immunostimulatory drug conjugate PF-08046037 in cancer patients, citing "strategic business reasons" without any safety or efficacy concerns. This decision ends Pfizer's plans for this specific drug, although it does not impact the company's broader research into immunostimulatory drug conjugates.
Pfizer's termination of the phase 1 trial for PF‑08046037 due to "strategic business reasons," rather than safety or efficacy concerns, suggests potential shifts in focus or resource allocation within...
<a href="https://www.fiercehealthcare.com/health-tech/cms-fda-announce-new-program-speed-medicare-coverage-breakthrough-medical-devices" hreflang="en">CMS, FDA announce new program to speed up Medicare coverage of breakthrough medical devices</a>
fiercehealthcare.com·Apr 23, 2026
The CMS and FDA have launched the RAPID coverage pathway to expedite Medicare coverage for breakthrough medical devices, aiming to reduce delays between FDA approval and Medicare reimbursement. This program enhances collaboration between the two agencies and allows for quicker access to innovative therapies for Medicare beneficiaries.
The CMS and FDA have introduced the RAPID coverage pathway, which significantly speeds up Medicare coverage for FDA-designated Class II and III breakthrough devices by aligning evidentiary expectation...
STAT+: Can Erasca be biotech’s next big thing? We’ll see
statnews.com·Apr 23, 2026
Erasca, a biotech company with a market value nearing $7 billion, aims to develop a superior pan-RAS inhibitor for pancreatic cancer, competing with Revolution Medicines, which currently has a market value exceeding $30 billion. The company's potential to become a significant player in the biotech industry will be assessed following the upcoming results from an early-stage study of its drug, ERAS-0015.
Erasca's potential as a significant player in biotech hinges on the upcoming initial results from an early-stage study of its pan-RAS inhibitor for pancreatic cancer, ERAS-0015. With its market value ...
STAT+: Will bargain-basement telehealth visits help pharma drive drug scripts?
statnews.com·Apr 23, 2026
The article discusses concerns over the growing ties between telehealth providers and pharmaceutical companies, particularly regarding discounted telehealth visits that may lead to increased prescriptions of expensive branded drugs. Experts warn that these partnerships could violate anti-kickback laws and promote unnecessary medication use.
The article highlights a growing concern over the intertwining of telehealth services and pharmaceutical companies, where discounted telehealth visits are used to drive prescriptions for specific drug...
<a href="https://www.fiercebiotech.com/biotech/debt-acceptable-prices-roche-ceo-lists-3-reasons-sitting-out-big-pharma-deal-spree" hreflang="en">From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree</a>
fiercebiotech.com·Apr 23, 2026
Roche's CEO, Thomas Schinecker, explained the company's decision to refrain from participating in the recent Big Pharma M&A spree, citing concerns over debt, a lack of urgent need due to a strong pipeline of upcoming drug launches, and a focus on avoiding overpaying for acquisitions. Roche has previously made significant acquisitions but is currently prioritizing financial prudence and maintaining growth momentum without incurring additional debt.
Roche's strategic decision to abstain from the recent M&A frenzy highlights a cautious approach in the current high-interest rate environment, aiming to avoid incurring debt and focusing on sustainabl...
<a href="https://www.fiercebiotech.com/biotech/sanofi-interim-ceo-defends-hudsons-dupixent-legacy-accepts-number-setbacks-rd" hreflang="en">Sanofi CFO defends Hudson’s Dupixent legacy, but accepts ‘number of setbacks’ in R&D</a>
fiercebiotech.com·Apr 23, 2026
Sanofi's CFO acknowledged setbacks in R&D during Paul Hudson's leadership, including failed trials, but emphasized the company's overall transformation and revenue growth, particularly with the success of Dupixent. As the company prepares for new CEO Belén Garijo, there are plans to reassess its R&D strategy and therapeutic areas.
Sanofi's recent leadership transition and its focus on strengthening R&D productivity and innovation under incoming CEO Belén Garijo, M.D., Ph.D., present a strategic opportunity to track potential sh...
STAT+: At AACR, talk of Chinese biotech, oncology’s comms issue, and more
statnews.com·Apr 22, 2026
At the AACR conference, Revolution Medicines showcased promising data on their new compound RM-055, which could potentially combat cancer resistance to RAS inhibitors by turning off multiple mutant RAS proteins. Additionally, discussions highlighted the increasing sophistication of Chinese biotech research and the need for improved communication in oncology.
Revolution Medicines has introduced RM-055, a novel catalytic inhibitor, which shows promise in overcoming cancer resistance by turning off multiple mutant RAS proteins. This advancement is particular...
Pharma-backed petition calls on FDA to reform release of drug rejection letters
endpts.com·Apr 22, 2026
A petition backed by the pharmaceutical industry is urging the FDA to reform its practice of publicly releasing partially redacted drug rejection letters, highlighting growing criticism of this new approach.
The most valuable insight for you is the growing industry pushback against the FDA's practice of publicly releasing partially redacted drug rejection letters. This development signals a potential shif...
Nektar Therapeutics has announced a $325 million public offering, selling approximately 3.5 million shares at $92 each. The news comes amidst rising stock for Maze Therapeutics and rumors of a Merck deal, alongside layoffs at Bristol-Myers Squibb.
The content does not provide relevant insights specific to your areas of interest in healthtech, biotech, or digital health. It mainly discusses financial offerings and stock movements in the biopharm...
STAT+: Gene therapy trial for deafness adds evidence to drug’s efficacy
statnews.com·Apr 22, 2026
A recent gene therapy trial in China showed that 90% of participants, primarily deaf children, experienced significant improvements in hearing, with some even able to hear whispers. This promising result adds to the growing consensus that the therapy is effective for treating a rare type of congenital hearing loss.
The gene therapy targeting the OTOF gene has shown promising efficacy, with 90% of participants in a Chinese clinical trial reporting significant hearing improvement, including in some adults up to 32...
<a href="https://www.fiercebiotech.com/biotech/lilly-reneges-remainder-rigel-deal-another-blow-ripk1-inhibitors" hreflang="en">Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors</a>
fiercebiotech.com·Apr 22, 2026
Eli Lilly has terminated its licensing agreement with Rigel Pharmaceuticals for the RIPK1 inhibitor ocadusertib, citing unmet development standards, following a previous withdrawal from the CNS-focused portion of the deal. This decision adds to ongoing challenges in the RIPK1 inhibitor field, with other companies also facing setbacks.
The repeated setbacks in the development of RIPK1 inhibitors, highlighted by Eli Lilly's withdrawal from its partnership with Rigel Pharmaceuticals, suggest a critical need for reevaluation of this th...
STAT+: The latest biotech news: RevMed, Roche, Kyverna CAR-T therapy
statnews.com·Apr 22, 2026
The latest biotech news highlights Revolution Medicines previewing a next-generation RAS-inhibiting drug and Roche's developments in CAR-T therapy for autoimmune diseases, amidst ongoing challenges with Medicare's coverage of obesity drugs for seniors.
The content mentions that RevMed is previewing a next-generation RAS inhibiting drug. For someone tracking AI drug discovery and precision medicine, this development may signal a significant advanceme...
AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.
techcrunch.com·Apr 22, 2026
10x Science, a startup founded in December 2025, has raised $4.8 million to help pharmaceutical researchers characterize potential drug candidates generated by AI, addressing a bottleneck in drug development. The platform combines chemistry, biology, and AI to interpret complex data from mass spectrometry, aiming to streamline the drug discovery process and enhance regulatory compliance.
10x Science's platform, which combines deterministic algorithms with AI to interpret mass spectrometry data, offers a scalable solution for drug discovery by streamlining the characterization of compl...
<a href="https://www.fiercebiotech.com/biotech/kurma-closes-252m-vc-vehicle-coming-short-its-target-ahead-prior-fund" hreflang="en">Kurma closes €215M Europe-focused fund to spread across 20 biotechs</a>
fiercebiotech.com·Apr 22, 2026
Kurma Partners has successfully closed its fourth biotech venture capital fund, raising €215 million ($252 million) to invest in 16 to 20 European startups, despite falling short of its €250 million target. The fund aims to bridge the gap between scientific discovery and venture capital financing, with existing investments including companies focused on obesity and antibody-drug conjugates.
Kurma Partners' €215M Biofund IV underscores the growing focus on European biotech startups, despite falling short of its original target. This fund highlights significant opportunities for investing ...
<a href="https://www.fiercebiotech.com/medtech/mckesson-swaps-minority-stake-surgical-unit-apollo-funds-125b" hreflang="en">McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B</a>
fiercebiotech.com·Apr 22, 2026
McKesson has sold a 13% minority stake in its medical/surgical solutions division to Apollo Funds for $1.25 billion as part of its strategy to prepare the unit for an initial public offering next year, while maintaining majority ownership and operational control. This deal values the division at approximately $13 billion and aims to support its growth amidst recent sluggish performance.
McKesson's strategic move to divest a minority stake of its medical/surgical solutions division to Apollo Funds for $1.25 billion, with an eye on a future IPO, signals an opportunity to track the divi...
Build your own newsroom
Add your own sources, define your topics, and get personalized digests delivered to your inbox.